PSS World signs distribution deal with Philips
PSS World Medical’s subsidiary, Diagnostic Imaging, signed an agreement with Philips Medical Systems North America last month that gives DI exclusive distribution rights to Philips’ Tomoscan EG CT and BV25 Gold Mobile C-arm systems. The deal
PSS World Medicals subsidiary, Diagnostic Imaging, signed an agreement with Philips Medical Systems North America last month that gives DI exclusive distribution rights to Philips Tomoscan EG CT and BV25 Gold Mobile C-arm systems. The deal also gives Jacksonville, FL-based DI the nonexclusive right to market Philips computed radiography and BV300 Series Mobile C-arm units. DIs goal is to sell $12 million of Philips equipment and services during the first year of the agreement, according to company executives.
In other DI news, the subsidiary added four companies to its distribution network last month in cash purchase transactions. The acquisitions will increase DIs revenue each year by approximately $15 million, and include South Florida MedX of Florida, Valley Imaging of Wisconsin, Southwest Medical Services of Arizona, and Long Island Imaging Specialists of New York.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
